{"entity":{"id":"ighv-status","kind":"term","name":"IGHV mutational status","aka":[],"tldr":"Whether the leukaemia's antibody gene has been 'edited' by the immune system. Unmutated means faster-growing CLL and a bigger benefit from targeted drugs over chemotherapy.","summary":"IGHV genes with <2% deviation from germline are 'unmutated' (~40-50% of CLL) and predict shorter time to treatment and poor response to chemoimmunotherapy (FCR). BTK inhibitors and venetoclax combinations largely erase the difference for progression, and IGHV status is a stratification factor in every modern CLL trial (CLL13, AMPLIFY). Mutated-IGHV patients still achieve the longest remissions after fixed-duration therapy.","asOf":"2026-09-07","wikipedia":"https://en.wikipedia.org/wiki/Chronic_lymphocytic_leukemia","links":[{"label":"Wikipedia","url":"https://en.wikipedia.org/wiki/Chronic_lymphocytic_leukemia"}],"tags":[],"related":[],"cancers":["cll"],"sections":[],"technologies":["cgp"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"category":"Biomarkers"},"route":"/terms/ighv-status/","neighbours":{"cancer":[{"id":"cll","kind":"cancer","name":"Chronic lymphocytic leukaemia","route":"/cancers/cll/"},{"id":"cll-treatment-naive","kind":"cancer","name":"Chronic lymphocytic leukaemia, first treatment","route":"/cancers/cll-treatment-naive/"},{"id":"waldenstrom","kind":"cancer","name":"Waldenström macroglobulinaemia","route":"/cancers/waldenstrom/"}],"technology":[{"id":"cgp","kind":"technology","name":"Comprehensive genomic profiling","route":"/technologies/cgp/"}],"trial":[{"id":"amplify","kind":"trial","name":"AMPLIFY","route":"/trials/amplify/"},{"id":"cll13-gaia","kind":"trial","name":"CLL13 / GAIA","route":"/trials/cll13-gaia/"}],"idea":[{"id":"idea-mrd-guided-stop-cll","kind":"idea","name":"MRD-guided treatment duration in CLL","route":"/ideas/idea-mrd-guided-stop-cll/"}],"paper":[{"id":"paper-cll14-venetoclax-obinutuzumab-nejm-2019","kind":"paper","name":"CLL14: one year of venetoclax plus obinutuzumab instead of chemo-immunotherapy in older, less fit CLL patients","route":"/key-papers/paper-cll14-venetoclax-obinutuzumab-nejm-2019/"}],"term":[{"id":"cll-ipi","kind":"term","name":"CLL-IPI (chronic lymphocytic leukaemia prognostic index)","route":"/terms/cll-ipi/"}],"institution":[{"id":"northwell-cancer-institute","kind":"institution","name":"Northwell Health Cancer Institute","route":"/institutions/northwell-cancer-institute/"}]}}